Verseon Showcases Diabetic Eye Disease Oral Drug Candidates At BIO Worldwide Convention

Verseon introduced an alternative To Eye Injections For Diabetic Macular Edema Patients, solving one of the biggest problems of Diabetic patients. For decades, millions of diabetic patients around the world who have continually battled diabetes and extremely high sugar levels have had their health conditions escalate to full-blown DME.

DME means Diabetes Macular Edema, it originates from incurable high blood sugar and it is a primary trigger of blindness in adults. Its potential for blindness is owed to the fact that patients suffering from it experience leakage of blood and fluids from blood vessels. These fluids and blood then go on to gather in the macula section of the retina (the part that controls the most elaborate part of our visions) and therefore result in blindness.

Be that as it may, diverse ways have been used to treat this eye condition such as the use of eye Injections and lasers. However, quite recently, oral drugs are being invented by Verseon. Medical practitioners say it could be the best treatment method that we’ve all been waiting for. Let’s discuss it’s existence and the role that Verseon has played.

Oral Drugs As A Replacement For Eye Injections.

In line with the traumatizing effects of DME, medical science has sourced out ways of treating this health condition. For years several treatment methods such as laser treatment which seals off leaking blood vessels, lucentis, eylea, or avastin injections which are injected in the eye and intravitreal steroids which are also injected into the eyes have been engaged.

Going on, while these eye Injections have been potent to an extent, they have also been inconveniencing by virtue of their method of administration. What’s more, patients that the injections have been administered on, have made complaints of inflammation, infection, and discomforts. This, therefore, has led to oral drugs being considered as a replacement to eye Injections and a preventive measure against DME. Verseon on its part is playing a major role in the evolution of things. The company is doing this by preparing the first oral medications.  

Verseon Offers Oral Drug Candidates Towards The Treatment Of DME.

Verseon, the American pharmaceutical company based in California, understanding the side effects of eye injections and that these Injections have proven to be efficient in only about half of diabetic patients suffering from DME have gone on to offer oral drug candidates for DME. The company did this at the 2019 Bio international convention that held in Philadelphia this week. These oral drug candidates could be proof that millions of diabetics facing the risk of loss of vision need to believe that there is a drug more potent than eye injections for treating and preventing DME.

Flowing from the above, at the convention, Dr. Anirban Datta the senior director of discovery biology with Verseon company expressed that the drug would revolutionize the way DME is treated. He also went on to present preclinical data that shows that the drug primarily fights plasma kallikrein, a central aspect of the disease that is not combated by current eye injections. The results so far have been impressive as retinal vascular leakage and retinal thickening (two primary influencers of DME) have been inhibited. That said, the company is presently making the first to the scene development prospects for the first phase of trials. It’s success is foreseen to launch a ninety six billion dollars yearly worldwide market for prophylaxis and treatment.   

All You Should Know About Verseon.

Verseon is an American based pharmaceutical company that’s driven by the need to advance global health. The company makes use of its computational and advanced drug discovery platform to develop new drugs that are less likely to be developed if conventional methods were used. Having combined its computational platform with a well detailed in house biology and chemistry workflow, Verseon has successfully created diverse drug programs. The company’s drug programs are oncology, anticoagulation, hereditary angioedema and diabetic macular edema. Find Verseon on Twitter and LinkedIn. Or on the website:

On a final note, research has it that the global diabetic population is at four hundred and twenty five million and in the next twenty five years, this population is estimated to be at six hundred million. As diabetic individuals increase, diabetic macula edema patients are likely to increase. Verseon pharmaceuticals understanding the difficulty involved in battling DME and the side effects associated with treating DME with eye injections and lasers, has decided to go all out towards creating a drug that can be administered orally. It’s effects would not just be the cure of DME, it would also be the prevention of the health condition. So diabetes patients would be able to live life to the fullest without experiencing the horrors of adult blindness.

To Top

Pin It on Pinterest

Share This